Vaccine containing cancer cells inactivated by photodynamic treatment with metal-based coordination complexes, and immunotherapy method using same
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11464798-B2
Publication Date
2022-10-11
Expiration Date
Abstract
A method for treating a tumor in a patient by administering to the patient an immunogenic composition including antigenic material inactivated by treatment with a metal-based coordination complex and electromagnetic radiation, wherein the immunogenic composition is effective to elicit an immune response to the antigenic material in the patient after administration and the metal-based coordination complex having a specified formula. An immunogenic composition and a method for preparing it are also disclosed.
Core Innovation
The invention relates to treating a tumor in a patient by administering an immunogenic composition comprising antigenic material inactivated by treatment with a metal-based coordination complex and electromagnetic radiation. The immunogenic composition is effective to elicit an immune response to the antigenic material in the patient after administration. The metal-based coordination complex is represented by defined formulas including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof.
The metal-based coordination complex is further defined through formula selections including formula (I), formula (VI), and formula (VIIa), with component constraints for M, X, and bidentate ligands (Lig). The formulas define metal centers selected from osmium, ruthenium, rhodium and other listed metals, and counterions X selected from a defined set. The bidentate ligand framework includes R substituent options and integer parameters.
An additional aspect of the invention provides a method for preparing the immunogenic composition by collecting tumor cells from a donor, preparing a composition comprising the tumor cells and the metal-based coordination complex, and exposing the composition to electromagnetic radiation to provide the immunogenic composition. The electromagnetic radiation is defined to include laser light and alternative modalities such as X-rays and gamma rays.
Claims Coverage
The independent claims cover two main aspects: treating a tumor in a patient using an immunogenic composition containing antigenic material inactivated with a metal-based coordination complex and electromagnetic radiation, and preparing that immunogenic composition by combining donor tumor cells with the metal-based coordination complex and exposing the combination to electromagnetic radiation. Across these independent claims, the inventive content is concentrated in the inactivation concept and the specifically defined metal-based coordination complex formulas.
Tumor treatment using inactivated antigenic material with a metal-based coordination complex and electromagnetic radiation
Administering to the patient an immunogenic composition comprising antigenic material inactivated by treatment with a metal-based coordination complex and electromagnetic radiation, where the immunogenic composition is effective to elicit an immune response to the antigenic material in the patient after administration.
Metal-based coordination complex represented by defined coordination-complex formulas
The metal-based coordination complex is represented by one of the following formulas, including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, with M and X selection and bidentate ligand definitions as specified in the formulas.
Preparing an immunogenic composition by collecting tumor cells, adding the metal-based coordination complex, and exposing to electromagnetic radiation
Collecting tumor cells from a donor; preparing a composition comprising the tumor cells and a metal-based coordination complex; and exposing the composition to electromagnetic radiation to provide the immunogenic composition.
Immunogenic composition effective to elicit immune response after administration
The immunogenic composition is effective to elicit an immune response to the antigenic material in a patient to whom the immunogenic composition is administered.
Taken together, the independent claims define a tumor immunotherapy concept in which antigenic material is inactivated using a specifically defined metal-based coordination complex and electromagnetic radiation to form an immunogenic composition. The independent claims also specify that the coordination complex used in both treatment and preparation is limited to one of several coordination-complex formulas with defined metal/counterion and ligand/substituent constraints, including permitted salt, solvate, and prodrug forms.
Stated Advantages
Elicits an immune response to the antigenic material in the patient after administration.
Documented Applications
Treating a tumor in a patient by administering an immunogenic composition comprising antigenic material inactivated by treatment with a metal-based coordination complex and electromagnetic radiation.
Preparing an immunogenic composition for administration to a patient to elicit an immune response to antigenic material.
Interested in licensing this patent?